Leerink Partners Remains Bullish on Merck & Co. (MRK)

Merck & Co., Inc. (NYSE:MRK) is one of the best affordable growth stocks to buy. On August 26, Leerink Partners analyst Daina Graybosch maintained a Buy rating on Merck & Co., Inc. (NYSE:MRK) and set a $107.00 price target.

The firm supported the optimistic rating with Merck & Co., Inc.’s (NYSE:MRK) clinical trials, stating that the successful results from the HARMONi-A study reflect the potential of the VEGF-A/PD-(L)1 class for the treatment of particular lung cancer types.

Graybosch added that another significant factor supporting Merck & Co., Inc.’s (NYSE:MRK) positive outlook is the potential for bispecifics to serve as a backbone for novel combinations in global studies. This would position Merck & Co., Inc. (NYSE:MRK) to maximize value.

Merck & Co., Inc. (NYSE:MRK) is a biopharmaceutical company that delivers health solutions to advance the treatment and prevention of diseases in animals and people.

Its Pharmaceutical segment offers vaccines and human health pharmaceutical products, typically therapeutic and preventive agents. Its Animal Health segment develops, discovers, manufactures, and markets a range of vaccines and veterinary pharmaceutical products.

While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.